Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.
Official Title
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Quick Facts
Study Start:2018-10-11
Study Completion:2025-09-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:TERMINATED
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
Banner University Medical Center Phoenix
Phoenix, Arizona, 85006
United States
Asian Pacific Liver Center at Coalition of Inclusive Medicine
Los Angeles, California, 90020
United States
California Liver Research Institute
Pasadena, California, 91105
United States
Stanford University
Redwood City, California, 94063
United States
UC Davis GI/Hepatology Clinical Trials Unit
Sacramento, California, 95817
United States
Silicon Valley Research Institute
San Jose, California, 95128
United States
Yale University Digestive Diseases
New Haven, Connecticut, 06520
United States
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, 20007
United States
University of Florida
Gainesville, Florida, 32610-0272
United States
University of Miami, Schiff Center for Liver Disease
Miami, Florida, 33136
United States
Consultative Gastroenterology
Atlanta, Georgia, 30308
United States
Atlanta Gastroenterology
Atlanta, Georgia, 30342
United States
Rush Universtiy Medical Center
Chicago, Illinois, 60612
United States
University of Chicago
Chicago, Illinois, 60637
United States
Mercy Medical Center
Baltimore, Maryland, 21202
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Minnesota Gastroenterology, P.A.
Plymouth, Minnesota, 55446
United States
Rutgers, Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901
United States
Dreamwork Medical, PLLC
Flushing, New York, 11354
United States
Northwell Health Center for Liver Diseases and Transplantation
Manhasset, New York, 11030
United States
NYU Langone Health
New York, New York, 10016
United States
Weill Cornell Medical College
New York, New York, 10021
United States
Columbia University Medical Center
New York, New York, 10032
United States
UNC Liver Center
Chapel Hill, North Carolina, 27599
United States
UT Southwestern Medical Center
Dallas, Texas, 75390
United States
Digestive and Liver Disease Specialist
Norfolk, Virginia, 23502
United States
Bon Secours Liver Institute of Richmond
Richmond, Virginia, 23226
United States
Virginia Commonwealth University
Richmond, Virginia, 23298
United States
Swedish Organ Transplant and Liver Center
Seattle, Washington, 98104
United States
University of Washington/Harborview Medical Center
Seattle, Washington, 98104
United States
Collaborators and Investigators
Sponsor: Target PharmaSolutions, Inc.
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2018-10-11
Study Completion Date2025-09-10
Study Record Updates
Study Start Date2018-10-11
Study Completion Date2025-09-10
Terms related to this study
Additional Relevant MeSH Terms
- Hepatitis B
- Hepatitis
- Liver Diseases